Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits

Journal of Medicinal Chemistry

Volumn 49, Issue 23, 2006, Pages 6638-6641

  Ulven, Trond ^a,b   Receveur, Jean Marie ^a   Grimstrup, Marie ^a   Rist, Øystein ^a   Frimurer, Thomas M ^a   Gerlach, Lars Ole ^a   Mathiesen, Jesper Mosolff ^a   Kostenis, Evi ^a,c   Uller, Lena ^a,d   Högberg, Thomas ^a  

^a 7TM Pharma ^*  (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF BONN   (Germany)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 BROMO 2 (1 PHENYL 1H PYRAZOLE 4 CARBONYL)PHENOXYACETIC ACID; ANGIOTENSIN 1 RECEPTOR; INDOMETACIN; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING COMPETITION; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; CELL HYPERPLASIA; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SOLUBILITY; EOSINOPHIL; EOSINOPHILIA; IC 50; INFLAMMATION; MOUSE; NONHUMAN; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; TH2 CELL;

ACETIC ACIDS; ANIMALS; ANTI-ALLERGIC AGENTS; ASTHMA; BINDING, COMPETITIVE; BIOLOGICAL AVAILABILITY; EOSINOPHILS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; INFLAMMATION; MICE; MODELS, MOLECULAR; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TH2 CELLS;

EID: 33750978443     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060657g     Document Type: Article

References (23)

1. (a) Lewis, R. A.; Suter, N. A.; Diamund, P. T.; Austen, K. F.; Gates, J. A.; Roberts, L. J., II. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J. Immunol. 1982, 129, 1627-1631.
2. (b) Murray, J. J.; Tonnel, A. B.; Brash, A. R.; Roberts, L. J., II; Gosset, P.; Workman, R.; Capron, A.; Gates, J. A. Release of prostaglandin D2 into human airways during acute antigen challenge. N. Engl. J. Med. 1986, 315, 800-804.
3. Fujitani, Y.; Kanaoka, Y.; Aritake, K.; Uodome, N.; Okazaki-Hatake, K.; Urade, Y. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J. Immunol. 2002, 168, 443-449.
4. Reviews with relevant references therein: (a) Kostenis, E.; Ulven, T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol. Med. 2006, 12, 148-158.
5. (b) Herlong, J. L.; Scott, T. R. Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol. Lett. 2006, 102, 121-131.
6. Moore, M. L.; Peebles, R. S., Jr.; Update on the role of prostaglandins in allergic lung inflammation: Separating friends from foes, harder than you might think. J. Allergy Clin. Immunol. 2006, 117, 1036-1039.
7. Hata, A. N.; Breyer, R. M. Pharmacology and signaling of prosta-glandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol. Ther. 2004, 103, 147-166.
8. Hirata, M.; Kakizuka, A.; Aizawa, M.; Ushikubi, F.; Narumiya, S. Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 11192-11196.
9. (a) Nagata, K.; Hirai, H.; Tanaka, K.; Ogawa, K.; Aso, T.; Sugamura, K.; Nakamura, M.; Takano, S. CRTH2, an orphan receptor of T-helper-2-cells, is expressed on basophils and eosinophils and responds to mast cell-derived factor(s). FEBS Lett. 1999, 459, 195-199.
10. (b) Hirai, H.; Tanaka, K.; Yoshie, O.; Ogawa, K.; Kenmotsu, K.; Takamori, Y.; Ichimasa, M.; Sugamura, K.; Nakamura, M.; Takanu, S.; Nagata, K. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seventransmembrane receptor CRTH2. J. Exp. Med. 2001, 193, 255-261.
11. Shiraishi, Y.; Asano, K.; Nakajima, T.; Oguma, T.; Suzuki, Y.; Shiomi, T.; Sayama, K.; Niimi, K.; Wakaki, M.; Kagyo, J.; Ikeda, E.; Hirai, H.; Yamaguchi, K.; Ishizaka, A. Prostaglandin D2-induced eosinophilic airway inflammation is mediated by CRTH2 receptor. J. Pharmacol. Exp. Ther. 2005, 312, 954-960.
12. Bohm, E.; Sturm, G. J.; Weiglhofer, I.; Sandig, H.; Shichijo, M.; McNamee, A.; Pease, J. E.; Kollroser, M.; Peskar, B. A.; Heinemann, A. 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. J. Biol. Chem. 2004, 279, 7663-7670.
13. Sawyer, N.; Cauchon, E.; Chateauneuf, A.; Cruz, R. P. G.; Nicholson, D. W.; Metters, K. M.; O'Neill, G. P.; Gervais, F. G. Molelcular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br. J. Pharmacol. 2002, 137, 1163-1172.
14. Ulven, T.; Kostenis, E. Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation. Curr. Top. Med. Chem. 2006, 6, 1427-1444.
15. (a) Arimura, A.; Yasui, K.; Kishino, J.; Asanuma, F.; Hasegawa. H.; Kakudo, S.; Ohtani, M.; Arita, H. Prevention of allergic inflammation by a novel prostaglandin receptor antagonist. S-5751. J. Pharmacol. Exp. Ther. 2001, 298, 411-419.
16. (b) Torisu, K.; Kobayashi, K.; Iwahashi, M.; Nakai, Y.; Onoda, T.; Nagase, T.; Sugimoto, I.; Okada, Y.; Matsumoto, R.; Nanbu, F.; Ohuchida, S.; Nakai, H.; Toda, M. Discovery of orally active prostaglandin D2 receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14, 4891-4895.
17. Mitsumori, S. Recent progress in work on PGD2 antagonists for drugs targeting allergic diseases. Curr. Pharm. Res. 2004, 10, 3533-3538.
18. Frimurer, T. M.; Ulven, T.; Filing, C. F.; Gerlach, L.-O.; Kostenis, F.; Högberg, T. A physicogenetic method to assign ligand-binding relationships between 7TM receptors. Bioorg. Med. Chem. Lett. 2005, 15, 3707-3712.
19. (a) Hirai, H.; Tanaka, K.; Takano, S.; Ichimasa, M.; Nakamura, M.; Nagata, K. Cutting edge: agonistic effect of indomethacin on a prostaglandin D2 receptor, CRTH2. J. Immunol 2002, 168, 981-985.
20. (b) Hata, A. N.; Lybrand, T. P.; Marnett, L. J.; Breyer, R. M. Structural determinants of arylacetic acid NSAIDs necessary for binding and activation of the PGD2 receptor CRTH2. Mol. Pharmacol. 2005, 67, 640-647.
21. Vrecl, M.; Jørgensen, R.; Pogacnik, A.; Heding. A. Development of a BRET2 screening assay using beta-arrestin 2 mutants. J. Biomol. Screening 2004, 9, 322-333.
22. Högberg, T.; Vora, M.; Drake, S.-D.; Mitscher, L. A.; Chu, D. T. W. Structure-activity relationships among DNA-gyrase inhibitors synthesis and antimicrobial evaluation of chromones and coumarins related to oxolinic acid. Acta Chem. Scand. 1984, B38, 359-366.
23. Uller, L.; Lloyd, C. M.; Rydell-Tormanen, K.; Persson, C. G.; Erjefält, J. S. Effects of steroid treatment on lung CC chemokines, apoptosis and transepithelial cell clearance during development and resolution of allergic airway inflammation. Clin. Exp. Allergy 2006, 36, 111-121.